Alto NeuroscienceANRO
ANRO
About: Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Employees: 88
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
278% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 9
48% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $7.05M
33% more capital invested
Capital invested by funds: $198M [Q2] → $264M (+$65.9M) [Q3]
30% more funds holding
Funds holding: 57 [Q2] → 74 (+17) [Q3]
15.64% more ownership
Funds ownership: 69.0% [Q2] → 84.64% (+15.64%) [Q3]
50% less funds holding in top 10
Funds holding in top 10: 4 [Q2] → 2 (-2) [Q3]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4
3%
upside
Avg. target
$10.50
170%
upside
High target
$18
363%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Jones Trading Justin Walsh 18% 1-year accuracy 2 / 11 met price target | 363%upside $18 | Buy Initiated | 16 Dec 2024 |
Stifel Paul Matteis 13% 1-year accuracy 2 / 15 met price target | 157%upside $10 | Buy Maintained | 13 Nov 2024 |
Wedbush Laura Chico 32% 1-year accuracy 20 / 62 met price target | 3%upside $4 | Neutral Downgraded | 23 Oct 2024 |
Baird Brian Skorney 29% 1-year accuracy 7 / 24 met price target | 157%upside $10 | Outperform Maintained | 23 Oct 2024 |
Financial journalist opinion
Based on 29 articles about ANRO published over the past 30 days
Neutral
Accesswire
8 hours ago
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 day ago
Alto Neuroscience, Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
2 days ago
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
3 days ago
Alto Neuroscience Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
4 days ago
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
5 days ago
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
6 days ago
The Schall Law Firm Encourages Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 week ago
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Affected Investors Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 week ago
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / December 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Neutral
Accesswire
1 week ago
Alto Neuroscience Inc Is Being Investigated For Securities Law Violations And Investors With Losses Are Invited To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alto Neuroscience, Inc. ("Alto Neuroscience" or "the Company") (NYSE:ANRO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Charts implemented using Lightweight Charts™